Publicaciones (375) Publicaciones de José Antonio Páramo Fernández

2024

  1. Factor XI inhibitors: A new era in antithrombotic therapy

    Medicina Clinica

  2. Novel biomarkers and psoriasis associated cardiovascular risk

    Archives of Dermatological Research, Vol. 316, Núm. 5

  3. Role of factor XIII in ischemic stroke: a key molecule promoting thrombus stabilization and resistance to lysis

    Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 4, pp. 1080-1093

  4. Transcriptomic Analysis of Extracellular Vesicles in the Search for Novel Plasma and Thrombus Biomarkers of Ischemic Stroke Etiologies

    International journal of molecular sciences, Vol. 25, Núm. 8

2023

  1. Critical bleeding-associated to DOACs administration

    Medicina Intensiva, Vol. 47, Núm. 12, pp. 733-735

  2. Immunothrombosis: Molecular Aspects and New Therapeutic Perspectives

    Journal of Clinical Medicine, Vol. 12, Núm. 4

  3. Loss of the matrix metalloproteinase-10 causes premature features of aging in satellite cells

    Frontiers in Cell and Developmental Biology, Vol. 11

  4. Multidisciplinary consensus document on the management of massive haemorrhage. First update 2023 (document HEMOMAS-II)

    Revista Espanola de Anestesiologia y Reanimacion, Vol. 70, Núm. 7, pp. 409-421

  5. Multidisciplinary consensus document on the management of massive haemorrhage. First update 2023 (document HEMOMAS-II)

    Medicina Intensiva, Vol. 47, Núm. 8, pp. 454-467

  6. Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI)

    Journal of Clinical Medicine, Vol. 12, Núm. 20

  7. Role of LCN2 in a murine model of hindlimb ischemia and in peripheral artery disease patients, and its potential regulation by miR-138-5P

    Atherosclerosis, Vol. 385

2022

  1. CM-352 Efficacy in a Mouse Model of Anticoagulant-Associated Intracranial Hemorrhage

    Thrombosis and Haemostasis, Vol. 122, Núm. 8, pp. 1314-1325

  2. Current status of diagnosis and treatment of heparin-induced thrombocytopenia (HIT)

    Medicina Clinica, Vol. 158, Núm. 2, pp. 82-89

  3. Estándares SEA 2022 para el control global del riesgo cardiovascular

    Clínica e investigación en arteriosclerosis, Vol. 34, Núm. 3, pp. 130-179

  4. Hemostatic Biomarkers and Volumetry Help to Identify High-Risk Abdominal Aortic Aneurysms

    Life, Vol. 12, Núm. 6

  5. Impact of the mutation profile on thrombotic risk in cancer patients

    Revista Clinica Espanola, Vol. 222, Núm. 2, pp. 93-99

  6. Inflammatory Response in Relation to COVID-19 and Other Prothrombotic Phenotypes

    Reumatologia Clinica, Vol. 18, Núm. 1, pp. 1-4

  7. Lipocalin-2 and Calprotectin Potential Prognosis Biomarkers in Peripheral Arterial Disease

    European Journal of Vascular and Endovascular Surgery, Vol. 63, Núm. 4, pp. 648-656

  8. Neutrophil-to-lymphocyte ratio as a cardiovascular risk biomarker in psoriasis: A comprehensive review

    JEADV Clinical Practice, Vol. 1, Núm. 4, pp. 397-406

  9. SEA 2022 Standards for Global Control of Cardiovascular Risk

    Clinica e Investigacion en Arteriosclerosis, Vol. 34, Núm. 3, pp. 130-179